Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
15 February 2023 - 8:05AM
Business Wire
Company to host conference call and webcast on
Monday, February 27, 2023, at 4:30 p.m. Eastern Time
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that
it will report fourth quarter and full year 2022 financial results
on Monday, February 27, 2023, after the close of the U.S. financial
markets. Acadia’s management team will also host a conference call
and webcast on February 27, 2023, at 4:30 p.m. Eastern Time to
discuss financial results and operations.
The conference call may be accessed by registering for the call
here. Once registered, participants will receive an email with the
dial-in number and unique PIN number to use for accessing the call.
The registration link will also be available on Acadia’s website,
www.acadia.com under the investors section and will be archived
there until April 3, 2023.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate
life. For more than 25 years we have been working at the forefront
of healthcare to bring vital solutions to people who need them
most. We developed and commercialized the first and only approved
therapy for hallucinations and delusions associated with
Parkinson’s disease psychosis. Our clinical-stage development
efforts are focused on treating the negative symptoms of
schizophrenia, Rett syndrome, Alzheimer’s disease psychosis and
neuropsychiatric symptoms in central nervous system disorders. For
more information, visit us at www.acadia.com and follow us on
LinkedIn and Twitter.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements regarding the
timing of future events. These statements are only predictions
based on current information and expectations and involve a number
of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to
various factors, including the risks and uncertainties inherent in
drug development, approval and commercialization. For a discussion
of these and other factors, please refer to Acadia’s annual report
on Form 10-K for the year ended December 31, 2021 as well as
Acadia’s subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
This caution is made under the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and Acadia undertakes no obligation to revise
or update this press release to reflect events or circumstances
after the date hereof, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230214005788/en/
Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818)
395-3043 media@acadia-pharm.com
Investor Contact: Acadia Pharmaceuticals Inc. Mark Johnson, CFA
(858) 261-2771 ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024